Weight-loss Drug Zepbound Eases Sleep Apnea in Company Trials

📆 17/04/2024 23:14:00
📰 MedicineNet

⏱ Reading Time:
10 sec. here
2 min. at publisher
📊 Quality Score:
News: 7%
Publisher: 51%

Weight Loss Drug Zepbound Eases Sleep Apnea In Com Notícia

Portugal Últimas Notícias,Portugal Manchetes

Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.

apnea "impacts 80 million adults in the U.S., with more than 20 million living with moderate-to-severe OSA. However, 85% of OSA cases go undiagnosed and therefore untreated," Dr. Jeff Emmick, senior vice president of product development at Lilly, said in a company news release announcing the results.

After 52 weeks, Zepbound prompted an average reduction of 27.4 events per hour in people who were not on PAP machines, compared to a reduction of 4.8 events per hour for people on a placebo.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Escrever Comentário

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Fonte: NBCNewsHealth - 🏆 707. / 51 Consulte Mais informação »